EPIRUS Biopharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $45,000. Loss from operations was $15,013,000 compared with $8,948,000 for the same period a year ago. Net loss was $15,286,000 or $0.65 per basic and diluted share compared with $9,890,000 or $28.71 per basic and diluted share for the same period a year ago.

For the six months, the company reported revenues of $70,000. Loss from operations was $22,235,000 compared with $15,170,000 for the same period a year ago. Net loss was $22,807,000 or $1.07 per basic and diluted share compared with $17,510,000 or $57.54 per basic and diluted share for the same period a year ago.